SEHK:6855Biotechs
Ascentage Pharma (SEHK:6855): Evaluating Valuation After ASH Meeting Spotlights Pipeline Progress
Ascentage Pharma Group International (SEHK:6855) saw attention rise after announcing that new clinical and preclinical results on olverembatinib, lisaftoclax, and APG-5918 will be featured at the 67th ASH Annual Meeting. This recognition for its drug candidates highlights the company’s development programs and keeps them in focus for investors.
See our latest analysis for Ascentage Pharma Group International.
This spotlight at ASH comes after a year of strong momentum for Ascentage Pharma...